Sector News

Flailing Wilex finds a lifeline as Roche steps in with an ADC deal

October 14, 2014
Life sciences
Germany’s Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.
 
Under the deal, Roche has agreed to pay as much as €52 million ($65.8 million) for the exclusive rights to an undisclosed tumor target. Roche also extended its relationship with Heidelberg Pharma, Wilex’s CRO subsidiary that out-licenses the biotech’s proprietary antibody-drug conjugate technology.
 
Wilex didn’t say how much of the sum comes in the form of up-front cash, but, for a company that has spent the past year struggling to keep the doors open, any income is a positive.
 
The Munich company’s problems began in 2012, when Rencarex, a renal cell carcinoma treatment, failed a Phase III trial. After a year of “intensive efforts” to find investors, Wilex let go of 80% of its staff in January and unveiled plans to gradually exit all clinical development, transitioning into a service provider.
 
So far, the company has signed over the Chinese rights to the Phase II pancreatic and breast cancer treatment Mesupron in a €7 million ($9.6 million) deal with Link Health, trading rest-of-the-world ownership of the drug to Israel’s RedHill Biopharma for $1 million up front and future royalties. And, in May, Wilex handed back 5 once-promising cancer treatments to ex-partner UCB in exchange for cancellation fees and some debt forgiveness.
 
Wilex co-founder and CEO Olaf Wilhelm stepped down in March after about 17 years with the company, replaced by CFO Jan Schmidt-Brand. The company, a Fierce 15 honoree back in 2005, was originally launched with the help of German billionaire Dietmar Hopp.
 
By Damian Garde
 
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]